Uveal melanoma Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | Delcath System, Versastem Oncology, BioMedValley Discoveries, Pfizer, Acrotech Pharma

Uveal melanoma emerging therapies such as Melphalan, Defacitinib (VS-6063) + VS-6766 (VH5126766), Ulixertinib (BVD-523), Binimetinib + Belinostat, and others are expected to boost the Uveal melanoma Market in the upcoming years.

DelveInsight has launched a new report on "Uveal melanoma - Market Insights, Epidemiology, and Market Forecast-2032" that delivers an in-depth understanding of the Uveal melanoma, historical and forecasted epidemiology as well as the Uveal melanoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Download sample report @ https://www.delveinsight.com/report-store/metastatic-uveal-melanoma-mum-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Recent advancements in the Uveal melanoma Market:
In September 2024, Aura announced the final results from Phase II trials of bel-sar, a first-line treatment for early-stage choroidal melanoma, a form of ocular melanoma affecting the inner eye (also referred to as uveal melanoma). Choroidal melanoma is a rare and aggressive cancer that presents serious risks to both vision and life. Radiation therapy for this condition often results in more than 85% irreversible vision loss, along with other severe comorbidities.

Some of the key facts of the Uveal melanoma Market Report:

The epidemiology section of the report presents both historical and projected data on Metastatic Uveal Melanoma across the 7MM, including the United States, EU4 countries (Germany, Spain, Italy, and France), the United Kingdom, and Japan, covering the period from 2019 to 2032.
Uveal melanoma is a rare disease, representing only 5% of all primary melanoma cases. However, it remains the most commonly diagnosed primary intraocular malignant tumor in adults. Early detection and localized treatment are essential, as survival rates are closely linked to the size of the primary tumor. Despite this, around 50% of patients eventually develop metastatic disease, with a survival period of approximately 6-12 months following metastasis diagnosis.
The epidemiology of Uveal Melanoma in the report is categorized into Total Incident Cases, Gender-Specific Cases, Age-Specific Cases, and Type-Specific Cases within the Metastatic Uveal Melanoma market.
Key Uveal melanoma companies such as Delcath System, Versastem Oncology, BioMedValley Discoveries, Pfizer, Acrotech Pharma, and others are evaluating new drugs for Uveal melanoma to improve the treatment landscape.
Promising Uveal melanoma pipeline therapies in various stages of development include Melphalan, Defacitinib (VS-6063) + VS-6766 (VH5126766), Ulixertinib (BVD-523), Binimetinib + Belinostat, and others.
To know more about the uveal melanoma market insights, visit: https://www.delveinsight.com/sample-request/metastatic-uveal-melanoma-mum-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Uveal melanoma market report:
Uveal melanoma market report covers a descriptive overview and comprehensive insight of the Uveal melanoma Epidemiology and Uveal melanoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Uveal melanoma market report provides insights on the current and emerging therapies.
Uveal melanoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Uveal melanoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Uveal melanoma market.

Got queries? Click here to know more about the Uveal melanoma Market Landscape https://www.delveinsight.com/report-store/metastatic-uveal-melanoma-mum-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Uveal melanoma Overview

The development of an effective screening tool for Metastatic Uveal Melanoma will be crucial for early detection and reducing mortality rates. Implementing proper screening methods can help lower the incidence of late-stage disease. Innovative companion diagnostic tests are expected to gain rapid acceptance among physicians and patients, facilitating earlier diagnoses. Additionally, the availability of novel genetic-profiling kits-covered by insurance-along with rising incidence rates and increased awareness, is likely to drive growth in the UM treatment market during the study period.

The primary objectives of ocular melanoma treatment are to eliminate the tumor, prevent recurrence and metastasis, and preserve vision. Current treatment options for Uveal Melanoma include surgery, radiation therapy, laser treatment, and photodynamic therapy. Laser therapy may be used in specific cases to destroy melanoma cells, while photodynamic therapy is primarily effective for smaller tumors. Photon radiotherapy has become a key treatment approach, demonstrating tumor control in 96% of cases and a five-year survival rate of 76%.

The market outlook is promising with the introduction of emerging therapies. Several key companies are advancing late-stage clinical trials for Metastatic Uveal Melanoma, including Immunocore with Tebentafusp, Bristol-Myers Squibb with Relatlimab, and Foghon Therapeutics with FHD 286, among others.

Uveal melanoma Market Outlook

The dynamics of the Uveal melanoma market is anticipated to change in the coming years owing to the expected launch of emerging therapies by key companies such as Delcath System, Versastem Oncology, BioMedValley Discoveries, Pfizer, Acrotech Pharma, and others during the forecast period 2019-2032.

Uveal Melanoma Marketed Drugs
Tebentafusp: Immunocore

Metastatic Uveal Melanoma Emerging Drugs

Relatlimab is a LAG-3-blocking antibody, which is being investigated for the treatment of metastatic UM, in combination with Nivolumab, as a key strategy to more effectively potentiate anti-tumor immune activity. Lymphocyte-activation gene 3 (LAG-3) is a cell-surface molecule expressed on effector T cells and regulatory T cells (Tregs) and functions to control T-cell response, activation and growth. In June 2021, US FDA granted Priority Review for the combination, as a treatment for UM, with an action target date of March, 2022.

FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM, two highly similar proteins that are the ATPases, or the catalytic engines across all forms of the BAF complex, one of the key regulators of the chromatin regulatory system. It is currently in Phase I to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 oral monotherapy in subjects with metastatic Uveal Melanoma (UM).

Explore more about the uveal melanoma therapies which are boosting the market in the upcoming years @ https://www.delveinsight.com/sample-request/metastatic-uveal-melanoma-mum-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Scope of the Uveal melanoma Market Report

Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Uveal melanoma Companies: Delcath System, Versastem Oncology, BioMedValley Discoveries, Pfizer, Acrotech Pharma, and others
Key Uveal melanoma Therapies: Melphalan, Defacitinib (VS-6063) + VS-6766 (VH5126766), Ulixertinib (BVD-523), Binimetinib + Belinostat, and others
Uveal melanoma Therapeutic Assessment: Uveal melanoma current marketed and Uveal melanoma emerging therapies
Uveal melanoma Market Dynamics: Uveal melanoma market drivers and Uveal melanoma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Uveal melanoma Unmet Needs, KOL's views, Analyst's views, Uveal melanoma Market Access and Reimbursement

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Uveal melanoma Patient Share (%) Overview at a Glance
5. Uveal melanoma Market Overview at a Glance
6. Uveal melanoma Disease Background and Overview
7. Uveal melanoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Uveal melanoma
9. Uveal melanoma Current Treatment and Medical Practices
10. Unmet Needs
11. Uveal melanoma Emerging Therapies
12. Uveal melanoma Market Outlook
13. Country-Wise Uveal melanoma Market Analysis (2019-2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Uveal melanoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Uveal melanoma Market Outlook 2032 https://www.delveinsight.com/report-store/metastatic-uveal-melanoma-mum-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Related Reports:

Uveal melanoma Pipeline Insights, DelveInsight

"Uveal melanoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Uveal melanoma market. A detailed picture of the Uveal melanoma pipeline landscape is provided, which includes the disease overview and Uveal melanoma treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.